Brozzetti Annalisa, Alimohammadi Mohammad, Morelli Silvia, Minarelli Viviana, Hallgren Åsa, Giordano Roberta, De Bellis Annamaria, Perniola Roberto, Kämpe Olle, Falorni Alberto
Department of Internal Medicine (A.B., S.M., V.M., A.F.), University of Perugia, 06126 Perugia, Italy; Department of Medical Sciences (M.A., O.K.), Science for Life Laboratory, Uppsala University, 750 03 Uppsala, Sweden; Centre of Molecular Medicine (M.A., A.H., O.K.), Department of Medicine (Solna), Karolinska Institutet, 171 76 Stockholm, Sweden; Division of Endocrinology, Diabetology, and Metabolism (R.G.), Department of Medical Sciences, University of Turin, 10126 Turin, Italy; Department of Cardio-Thoracic and Respiratory Science (A.D.B.), Endocrinology Unit, Second University of Naples, 80132 Naples, Italy; and Department of Pediatrics-Neonatal Intensive Care (R.P.), V. Fazzi Regional Hospital, 73100 Lecce, Italy.
J Clin Endocrinol Metab. 2015 May;100(5):1941-8. doi: 10.1210/jc.2014-3571. Epub 2015 Mar 3.
NACHT leucine-rich-repeat protein 5 (NALP5)/maternal antigen that embryo requires (MATER) is an autoantigen in hypoparathyroidism associated with autoimmune polyendocrine syndrome type 1 (APS1) but is also expressed in the ovary. Mater is an autoantigen in experimental autoimmune oophoritis.
The objectives of the study were to determine the frequency of NALP5/MATER autoantibodies (NALP5/MATER-Ab) in women with premature ovarian insufficiency (POI) and in patients with autoimmune Addison's disease (AAD) and to evaluate whether inhibin chains are a target for autoantibodies in POI.
Autoantibodies against NALP5/MATER and inhibin chains-α and -βA were determined by radiobinding assays in 172 patients with AAD without clinical signs of gonadal insufficiency, 41 women with both AAD and autoimmune POI [steroidogenic cell autoimmune POI (SCA-POI)], 119 women with idiopathic POI, 19 patients with APS1, and 211 healthy control subjects.
NALP5/MATER-Ab were detected in 11 of 19 (58%) sera from APS1 patients, 12 of 172 (7%) AAD sera, 5 of 41 (12%) SCA-POI sera, 0 of 119 idiopathic POI sera and 1 of 211 healthy control sera (P < .001). None of 160 POI sera, including 41 sera from women with SCA-POI and 119 women with idiopathic POI, and none of 211 healthy control sera were positive for inhibin chain-α/βA autoantibodies.
NALP5/MATER-Ab are associated with hypoparathyroidism in APS1 but are present also in patients with AAD and in women with SCA-POI without hypoparathyroidism. Inhibin chains do not appear to be likely candidate targets of autoantibodies in human POI.
NACHT富含亮氨酸重复蛋白5(NALP5)/胚胎所需母体抗原(MATER)是与1型自身免疫性多内分泌综合征(APS1)相关的甲状旁腺功能减退症中的一种自身抗原,但也在卵巢中表达。Mater是实验性自身免疫性卵巢炎中的一种自身抗原。
本研究的目的是确定卵巢早衰(POI)女性和自身免疫性艾迪生病(AAD)患者中NALP5/MATER自身抗体(NALP5/MATER-Ab)的频率,并评估抑制素链是否为POI中自身抗体的靶标。
通过放射结合试验在172例无性腺功能不全临床体征的AAD患者、41例患有AAD和自身免疫性POI[类固醇生成细胞自身免疫性POI(SCA-POI)]的女性、119例特发性POI女性、19例APS1患者和211名健康对照者中检测抗NALP5/MATER以及抑制素链α和βA的自身抗体。
在19例APS1患者的11份血清(58%)、172例AAD血清中的12份(7%)、41例SCA-POI血清中的5份(12%)、119例特发性POI血清中的0份以及211份健康对照血清中的1份中检测到NALP5/MATER-Ab(P<.001)。160份POI血清(包括41份SCA-POI女性的血清和119例特发性POI女性的血清)以及211份健康对照血清中均无抑制素链α/βA自身抗体呈阳性。
NALP5/MATER-Ab与APS1中的甲状旁腺功能减退症相关,但也存在于AAD患者和无甲状旁腺功能减退症的SCA-POI女性中。抑制素链似乎不太可能是人类POI中自身抗体的候选靶标。